Drug intelligence / Profile preview

SER-290

Development stage: Preclinical
Lead developer: Serina Therapeutics
Modality: Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

SER-290 is a preclinical-stage small molecule drug candidate being developed by Serina Therapeutics for the treatment of undisclosed central nervous system (CNS) disorders. The drug utilizes Serina's proprietary POZ (poly(2-oxazoline)) polymer platform, which is designed to enhance the delivery, solubility, and pharmacokinetic profile of therapeutic agents. By conjugating the active small molecule to the POZ polymer, the technology aims to provide controlled release and potentially improve the safety and efficacy profile compared to the unconjugated parent molecule. As of early 2024, the specific biological target and the exact CNS indication for SER-290 remain undisclosed by the company.

Beyond the preview

Go deeper on SER-290.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SER-290.

Explore the full profile